8月25日，上交所发布关于国泰海通证券股份有限公司2025年面向专业投资者公开发行公司债券（第四 期）（品种一）上市的公告。 依据《上海证券交易所公司债券上市规则》等规定，上交所同意国泰海通证券股份有限公司2025年面向 专业投资者公开发行公司债券（第四期）（品种一）于2025年8月26日起在上交所上市，并采取匹配成 交、点击成交、询价成交、竞买成交、协商成交交易方式。该债券证券简称为"25GTHT07"，证券代码 为"243544"。根据中国结算规则，可参与质押式回购。 来源：金融界 ...

Core Viewpoint - The company plans to utilize part of its temporarily idle raised funds for cash management to improve fund efficiency and increase returns for the company and its shareholders [6][9][10]. Summary by Sections Fundraising Overview - The company raised a total of RMB 75,880.00 million from its initial public offering (IPO) in August 2020, with a net amount of RMB 68,955.19 million after deducting issuance costs [1]. - In November 2023, the company raised RMB 18,830.26 million through a targeted issuance of shares, resulting in a net amount of RMB 18,342.53 million after expenses [2]. Investment Projects - The company disclosed that the funds from the IPO were allocated to a high-precision small power testing power supply and fuel cell, power semiconductor testing equipment production base construction project, with a planned use of RMB 27,646.23 million [3]. - The company has excess funds of RMB 41,308.96 million from the IPO, with plans to allocate the surplus to various projects, including a semiconductor testing and intelligent manufacturing equipment industrial park project [3][4]. Cash Management of Idle Funds - The company intends to use up to RMB 23,000 million of temporarily idle raised funds for cash management, with RMB 20,000 million from the IPO and RMB 3,000 million from the 2023 issuance [7][10]. - The cash management will involve investing in low-risk, high-liquidity financial products, ensuring that the funds are not used for non-raising purposes [7][8]. Board Approval and Compliance - The board of directors approved the cash management plan on August 22, 2025, ensuring that it does not affect the progress of investment projects or the safety of the raised funds [10]. - The company has complied with relevant regulations and internal policies regarding the management and use of raised funds, ensuring that the cash management does not alter the intended use of the funds [11].

Core Viewpoint - The company has completed the investment project of the "Semiconductor Testing and Intelligent Manufacturing Equipment Industrial Park" and plans to permanently supplement its working capital with the remaining raised funds, following the completion of the project and the approval of the board and shareholders [6][9][10]. Fundraising Overview - The company raised a total of RMB 758.8 million from its initial public offering, with a net amount of RMB 689.55 million after deducting issuance costs [1]. - The company established a special account for the management and use of the raised funds, ensuring compliance with regulatory requirements [2]. Investment Project Details - The company committed to invest RMB 276.46 million in the "High-Precision Small Power Testing Power Supply and Fuel Cell, Power Semiconductor Testing Equipment Production Base Construction Project" [2]. - The actual net amount raised was RMB 689.55 million, resulting in an excess of RMB 413.09 million after the planned investment [3]. Use of Excess Funds - The company decided to use RMB 120 million of the excess funds to permanently supplement working capital, which constitutes approximately 29.05% of the total excess funds [3][4]. - The remaining excess funds will be allocated to the "Semiconductor Testing and Intelligent Manufacturing Equipment Industrial Park Project," with a total investment of RMB 450 million, of which RMB 300 million will come from excess funds [4][5]. Project Completion and Surplus Funds - As of July 31, 2025, the project has completed its main construction and acceptance work, leading to the decision to conclude the project [6]. - The expected surplus funds amount to RMB 168.27 million, which includes interest and investment income, and will be used to permanently supplement working capital [8][9]. Impact on Company Operations - The decision to conclude the project and use surplus funds for working capital is aligned with the company's operational needs and long-term development strategy, enhancing cash flow and resource allocation [9][10]. - The company will maintain the special account for raised funds until all pending payments are settled, ensuring compliance with regulatory requirements [9]. Approval Process - The board of directors approved the proposal to conclude the investment project and use surplus funds on August 22, 2025, which will also require shareholder approval [10]. - The sponsor institution has confirmed that the decision complies with relevant regulations and is in the best interest of all shareholders [10][11].

Core Viewpoint - The report outlines the verification opinions of Guotai Junan Securities Co., Ltd. regarding the listing and circulation of strategic placement restricted shares of Zhongjuxin Technology Co., Ltd. after its initial public offering (IPO) on the STAR Market [1][4]. Group 1: Listing and Share Details - The restricted shares being listed are part of the strategic placement from the company's IPO, involving one shareholder, Haitong Innovation Securities Investment Co., Ltd., with a total of 11,583,011 shares, representing 0.78% of the company's total share capital [2][3]. - The total number of shares issued in the IPO was 369,319,000, with a total share capital of 1,477,276,000 shares post-IPO, where restricted shares account for 82.29% and unrestricted shares for 17.71% [1][2]. Group 2: Lock-up Period and Compliance - The lock-up period for the restricted shares is set for 24 months from the date of the IPO, which will expire on September 8, 2025 [2][3]. - The shareholder has adhered to all commitments made during the IPO process, and there are no unfulfilled commitments affecting the listing of the restricted shares [3][4]. Group 3: Verification and Conclusion - The sponsor institution confirms that all relevant regulations and requirements have been met regarding the listing and circulation of the restricted shares, and the information disclosed is accurate and complete [4].

国泰海通证券股份有限公司 关于上海奥浦迈生物科技股份有限公司 调整2025年度部分日常关联交易预计额度的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）首次公开 发行股票并在科创板上市持续督导的保荐机构，根据《证券发行上市保荐业务 管理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上 市公司自律监管指引第 1 号——规范运作》等相关法律、法规和规范性文件的 规定，对奥浦迈调整 2025 年度部分日常关联交易预计额度的的事项进行了专项 核查，核查情况与意见如下： 一、本次日常关联交易执行及调整情况 公司于 2025 年 4 月 14 日召开第二届董事会第八次会议、第二届监事会第 七次会议以及第二届董事会独立董事专门会议第二次会议分别审议通过了《关 于预计 2025 年度日常关联交易的议案》，同意公司（含子公司）对 2025 年度日 常关联交易额度进行预计，涉及金额合计 446.00 万元，主要用于向相关关联方 购买原材料、向关联方销售商品以及接受关联方提供的技术服务。关联董事肖 志华、张俊杰回避表决，获 ...

国泰海通证券股份有限公司 关于上海奥浦迈生物科技股份有限公司 首次公开发行部分限售股上市流通的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）首次公开 发行股票并在科创板上市持续督导的保荐机构，根据《证券发行上市保荐业务管 理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作》等法律法规的相关规定，对奥浦迈首次 公开发行部分限售股上市流通事项进行了核查，核查情况及核查意见如下： 一、本次上市流通的限售股类型 经中国证券监督管理委员会（以下简称"中国证监会"）于 2022 年 6 月 13 日出具的《关于同意上海奥浦迈生物科技股份有限公司首次公开发行股票注册的 批复》（证监许可〔2022〕1232 号），同意上海奥浦迈生物科技股份有限公司 （以下简称"奥浦迈"或者"公司"）首次公开发行股票的注册申请，并经上海证券 交易所同意，公司首次向社会公众公开发行人民币普通股 2,049.5082 万股，并于 本为 8,198.0328 万股，其中，有限售条件流通股 6,50 ...

Summary of Key Points Core Viewpoint The company intends to utilize part of its temporarily idle raised funds for cash management to enhance fund efficiency and maximize shareholder returns while ensuring compliance with regulations and maintaining the intended use of the raised funds [1][7]. Group 1: Fundraising and Management - The company raised a total of RMB 1,643,705,576.40 through its initial public offering, with a net amount after expenses being RMB 1,643,705,576.40 [1][2]. - All raised funds are managed in a dedicated account, with agreements in place between the company, its subsidiaries, and the commercial banks [2]. Group 2: Cash Management Plan - The company plans to use up to RMB 70,000.00 million of temporarily idle raised funds for cash management, with a rolling usage period of 12 months [3][4]. - The investment products will include safe and liquid options such as fixed deposits and structured deposits, ensuring that these funds are not used for pledging or securities investment [4]. Group 3: Approval and Oversight - The board of directors and the supervisory board have approved the cash management plan, confirming that it will not affect the normal operation of the fundraising projects [5][6]. - The supervisory board supports the plan, stating it will not harm the interests of the company or its shareholders [6]. Group 4: Compliance and Risk Management - The cash management activities are in compliance with relevant regulations and internal management systems, ensuring no change in the intended use of the raised funds [7]. - The company will implement strict risk control measures, focusing on high-security and high-liquidity investment products, while monitoring market conditions [5].

Summary of Key Points Core Viewpoint - The company is increasing the implementation subjects for certain fundraising projects and establishing a dedicated fundraising account to enhance the efficiency of fund usage and project execution, aligning with its overall development strategy [4][5][6]. Fundraising Basic Information - The company was approved to issue 30,707,070 shares at a price of 5.08 RMB per share, raising a total of 1,559,919,156 RMB, with a net amount of 1,418,966,238.97 RMB after deducting issuance costs [1]. Fund Usage Status - As of June 30, 2025, the total investment for the projects is 75,678.02 million RMB, with 75,000.00 million RMB already invested, indicating a significant progress in fund utilization [2]. New Implementation Subject - The company plans to establish a wholly-owned subsidiary, Ningbo Embodied Intelligent Robot Innovation Center Co., Ltd., to serve as the new implementation subject for the project "Industrial Digital Product Technology Upgrade Application and Medical Robot R&D" [3][4]. New Fundraising Account - A new fundraising account will be established to ensure proper management and usage of the funds, with agreements signed between the new subject, the company, and the commercial bank [4][5]. Reasons and Impact of Changes - The changes are driven by the actual needs of the company's business development, aiming to facilitate project execution without altering the investment direction or project content, thus ensuring resource allocation efficiency [4][6]. Review Procedures and Opinions - The board approved the changes without needing a shareholder meeting, and the supervisory board confirmed that the changes comply with relevant regulations and will not adversely affect the company's financial status or shareholder interests [4][5].

国泰海通证券股份有限公司 关于分众传媒信息技术股份有限公司本次交易 相关主体买卖股票情况的自查报告的核查意见 分众传媒信息技术股份有限公司（以下简称"分众传媒"、 "上市公司"或"公 司"）拟发行股份及支付现金向重庆京东海嘉电子商务有限公司、张继学、百度 在线网络技术（北京）有限公司等 50 名成都新潮传媒集团股份有限公司（以下 简称"标的公司"）股东购买其持有标的公司 100%股份（以下简称"本次交易"）。 国泰海通证券股份有限公司（以下简称"国泰海通证券"或"独立财务顾问"） 作为本次交易的独立财务顾问，根据《中华人民共和国证券法》《上市公司重大 《公开发行证券的公司信息披露内容与格式准则第 26 号—— 资产重组管理办法》 上市公司重大资产重组》及《监管规则适用指引——上市类第 1 号》《上市公司 监管指引第 5 号——上市公司内幕信息知情人登记管理制度》等法律法规和规范 性文件的规定，对本次交易相关主体买卖上市公司股票的情况进行了核查，具体 如下： 一、本次交易的相关主体买卖股票情况的自查期间 本次交易的相关主体买卖股票情况的自查期间为上市公司首次披露本次交 易事项或就本次交易申请股票停牌（孰早）前六 ...

国泰海通证券股份有限公司 关于东芯半导体股份有限公司部分募投项目结项 并将节余募集资金永久补充流动资金的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 东芯半导体股份有限公司（以下简称"东芯股份"或"公司"）首次公开发行股 票并在科创板上市持续督导的保荐机构，根据《中华人民共和国公司法》《中华 人民共和国证券法》《证券发行上市保荐业务管理办法》《上海证券交易所科创 板股票上市规则》《科创板上市公司持续监管办法（试行）》《上市公司募集资 金监管规则》以及《上海证券交易所科创板上市公司自律监管指引第 1 号——规 范运作》等有关法律法规和规范性文件的要求，对东芯股份部分募投项目结项并 将节余募集资金永久补充流动资金的事项进行了核查，核查情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会作出的《关于同意东芯半导体股份有限公司首 次公开发行股票注册的批复》（证监许可[2021]3558 号），并经上海证券交易所 同意，公司获准向社会公开发行人民币普通股 11,056.244 万股，每股面值人民币 扣除发行费用后的募集资金净额为人民币 306,358.16 万元。 国 泰 海 通 ...